- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07611474
To Evaluate the Safety and Effectiveness of Intrauterine Adhesion Preventer in the Prevention and Treatment of Intrauterine Adhesions, a Prospective, Multicenter, Randomized Controlled Clinical Trial
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Inte tillämpbar
Kontakter och platser
Studiekontakt
- Namn: Dabao MD
- Telefonnummer: 13017386201
- E-post: forxudabao@126.com
Studieorter
-
-
Hunan
-
Changsha, Hunan, Kina, 410013
- Rekrytering
- The Third XIANGYA Hospital of Central South University
-
Kontakt:
- Dabao MD
- Telefonnummer: 13017386201
- E-post: forxudabao@126.com
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
Tar emot friska volontärer
Beskrivning
Inclusion Criteria:
- Patients clinically diagnosed with intrauterine adhesions and with surgical indications (referring to those with fertility requirements or obstructed menstrual blood drainage) ② Women aged 20-40 years old; ③ Subjects voluntarily participated in the trial and signed informed consent.
Exclusion Criteria:
① Patients with obviously abnormal uterine cavity shape after surgery; those who could not clearly separate the normal uterine cavity anatomical morphology (i.e. bilateral or unilateral fallopian tube openings were not visible); those with reproductive organ malformations and uterine cavities that were too large or too small; those with recent uterine perforation; those with cervical insufficiency.
Those with a history of intrauterine adhesions and treatment;
Those with endometrial tuberculosis or suspected endometrial tuberculosis;
Those with adenomyosis or uterine fibroids>4cm;
Those with a history of malignant tumors or suspected malignant tumors;
Those with acute and chronic intrauterine infection and genital infection;
Those with unexplained vaginal bleeding or suspected uterine malignant lesions;
Those with severe anemia and abnormal coagulation function; those with a history of thrombosis; ⑨ Those in the acute stage of various diseases or severe systemic diseases;
Those with severe mental illness and physical weakness who cannot tolerate this operation;
⑪ Those with severe heart, liver, and kidney function diseases;
⑫ Those with contraindications to anesthesia or surgery;
⑬ Those who have participated in clinical trials in the past three months.
- Those who are considered unsuitable for inclusion by the researchers.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Förebyggande
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Experimental group
Uterine stent placement in the uterine cavity after hysteroscopic intrauterine adhesion separation surgery
|
After TCRA, uterine stents of different specifications were placed in the uterine cavity according to the different uterine cavity morphologies of the subjects, and the hysteroscope was inserted again to adjust the position of the uterine stent.
|
|
Experimentell: Control group
Uterine cavity insertion ring + balloon + sodium hyaluronate gel
|
The subjects were hospitalized for TCRA surgery.
After the surgery, different types of uterine rings were selected and inserted into the uterine cavity according to the morphology of the subjects' uterine cavity.
At the same time, a No. 12 Foley catheter was left in the uterine cavity, and 2.5 ml of normal saline was injected into the catheter balloon. 2 ml of hyaluronic acid gel was injected into the uterine cavity on one side of the catheter.
The doctor removed the Foley catheter on the first day after the surgery.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Intrauterine adhesion rate
Tidsram: At 12 months after the index hysterectomy
|
Refer to the 2017 American Fertility Association IUA guidelines AFS score.
AFS score: The case with adhesion whose total AFS score decreased by ≥ 4 points was considered effective.
The effective rate was calculated using the following formula: number of cases with total AFS score decreased by ≥ 4 points/total number of cases × 100%.
|
At 12 months after the index hysterectomy
|
Samarbetspartners och utredare
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- XY3-QX-ZGZ-1711A02
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .